Sign in
4

Changes in Ownership

Immunome Inc. Filed Acc 0001994071-26-000002

Chief Financial Officer sold 65,000 shares at an average $21.92 ($1,424,916)

  • Chief Financial Officer acquired 71,561 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Rosett Max Chief Financial Officer 2026-04-02 Option exercise 10b5-1 +31,848 $1.05 $33,440 79,324 D: show line 1 in the form
Rosett Max Chief Financial Officer 2026-04-02 Option exercise 10b5-1 +39,713 $1.35 $53,613 119,037 D: show line 2 in the form
Rosett Max Chief Financial Officer 2026-04-02 Sale 10b5-1 −63,656 $21.91 $1,394,703 55,381 D: show line 3 in the form
Rosett Max Chief Financial Officer 2026-04-02 Sale 10b5-1 −1,344 $22.48 $30,213 54,037 D: show line 4 in the form
Open-market sales · 65,000 sh · avg $21.92 · $1,424,916

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Rosett Max Chief Financial Officer 2026-04-02 Option exercise · Stock option (right to buy) 10b5-1 −31,848 60,000 D: show line 5 in the form
Rosett Max Chief Financial Officer 2026-04-02 Option exercise · Stock option (right to buy) 10b5-1 −39,713 0 D: show line 6 in the form
Loading xslF345X06/form4-04032026_110446.xml…